Auro Vaccines

Executive Summary

Auro Vaccines, a wholly-owned subsidiary of Aurobindo Pharma USA, is a clinical-stage biotechnology company pioneering a novel vaccine platform that precisely tunes immune responses for both preventive and therapeutic applications. Founded in 2020 and headquartered in Pearl River, New York, the company leverages a proprietary approach to design vaccines against infectious diseases by modulating the immune system's specificity. Currently in Phase 1 clinical development, Auro Vaccines aims to address unmet needs in areas such as respiratory infections and emerging pathogens. The company's platform has the potential to improve efficacy and safety profiles compared to traditional vaccines. With backing from a global pharmaceutical parent, Auro Vaccines is positioned to advance its lead candidate through early clinical trials, though it remains a high-risk, early-stage investment.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim safety and immunogenicity data readout60% success
• Q4 2026Announcement of strategic partnership or licensing deal for platform technology30% success
• H1 2027Initiation of Phase 2 study for lead vaccine candidate40% success